ArticleJournal of cosmetic dermatology2025
Comparison Combination of Autologous Fibroblast Cells Plus Platelet Rich Plasma (PRP) With PRP Alone in Treatment of Atrophic Acne Scars, a Split-Face Pilot Study With Biometric Assessment.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Platelet-Rich Plasma (PRP) bidirectionally modulates scar formation via the Piezo1-YAP/TAZ axis: a novel mechanotransduction hypothesis.Frontiers in cell and developmental biology · 2026Article
- Comparison Combination of Autologous Fibroblast Cells Plus Platelet Rich Plasma (PRP) With PRP Alone in Treatment of Atrophic Acne Scars, a Split-Face Pilot Study With Biometric Assessment.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAcne scars are a common side effect of acne vulgaris that can negatively impact patients' quality of life and contribute to depression and anxiety. There is no definitive treatment for this condition. Ongoing research aims to discover better therapeutic options for acne scars. This study was conducted to assess the efficacy and safety of autologous fibroblast injections with and without platelet-rich plasma (PRP) for this condition.
methodIn this split-face pilot study, eight patients with atrophic acne scars were injected with a PRP-fibroblast suspension on one side of their face, while the other side received only PRP as a control, in three biweekly sessions. Patients were assessed before treatment and 6 months later based on biometric indices, including skin ultrasound, hydration level, skin elasticity (R2, R5, and R7), the number of pores and spots, and the acne scar's volume, area, and depth.
resultsThe median differences in skin thickness before and after follow-up were 32.57 on the treatment side and 5.33 on the control side. These changes were significantly greater on the treatment side (p-value: 0.018). Improvements in skin elasticity (p-value: 0.012), skin hydration level (p-value: 0.028), the number of fine pores (p-value: 0.043), and the volume and area of scars (p-value: 0.043) were significantly better with the combination therapy. While the number of large pores and spots also improved significantly, the extent of improvement was comparable to that observed with PRP alone.
conclusionThe PRP-fibroblast suspension may be considered a novel and effective therapeutic approach for atrophic acne scars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.